News

Nectar Lifesciences Limited submitted a certificate to the National Stock Exchange of India Limited and BSE Limited on October 6, 2026, confirming compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, and received from Kfin Technologies Limited, the company’s registrar and share transfer agent, for the quarter ended September 30, 2026.

Nectar Lifesciences Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for dealing in securities of the company will be closed for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of financial results for the period ended September 30, 2026, in accordance with the company’s code of conduct as per SEBI regulations.

Nectar Lifesciences Limited informed the National Stock Exchange of India Limited and BSE Limited that its board of directors approved a change in the company`s corporate office from Plot No. 110, Industrial Area, Phase 1, Chandigarh 160 002 to Godrej Eternia, West Wing (Tower A), Plot No. 70, Industrial Area, Phase -1, Chandigarh, 160 002, effective September 15, 2026.

Net Loss of Nectar Lifescience reported to Rs 67.92 crore in the quarter ended March 2026 as against net loss of Rs 130.09 crore during the previous quarter ended March 2025. There were no Sales reported in the quarter ended March 2026 and during the previous quarter ended March 2025.For the full year,net loss reported to Rs 292.89 crore in the year ended March 2026 as against net loss of Rs 113.68 crore during the previous year ended March 2025. There were no Sales reported in the year ended March 2026 as against Rs 21.32 crore during the previous year ended March 2025.Powered by Capital Market - Live News

Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 30 May 2026.